PDF herunterladen
Semin Liver Dis 2009; 29(3): 297-306
DOI: 10.1055/s-0029-1233529
© Thieme Medical Publishers

Autoimmune Hepatitis in Children: What is Different from Adult AIH?

Giorgina Mieli-Vergani1 , Diego Vergani1
  • 1King's College London School of Medicine at King's College Hospital, Institute of Liver Studies, London, United Kingdom
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
12. August 2009 (online)

    Lizenzen und Reprints

ABSTRACT

Autoimmune hepatitis (AIH) is characterized by inflammatory liver histology, circulating non-organ-specific autoantibodies, and increased levels of immunoglobulin (Ig) G in the absence of a known etiology. Two types of childhood AIH are recognized according to seropositivity: smooth muscle antibody (SMA) and/or antinuclear antibody (ANA), which is AIH type 1; and antibodies to liver-kidney microsome type 1 (anti-LKM1), which is AIH type 2. There is a female predominance in both. Autoimmune hepatitis type 2 presents more acutely, at a younger age, and commonly with IgA deficiency; however, duration of symptoms before diagnosis, clinical signs, family history of autoimmunity, presence of associated autoimmune disorders, response to treatment, and long-term prognosis are similar in the two groups. Immunosuppressive treatment with steroids and azathioprine, which should be instituted promptly to avoid progression to cirrhosis, induces remission in 80% of cases. Relapses are common, often due to nonadherence. Drugs effective in refractory cases include cyclosporine and mycophenolate mofetil. Long-term treatment is usually required, with only some 20% of AIH type 1 patients able to discontinue therapy successfully. In childhood, sclerosing cholangitis with strong autoimmune features, including interface hepatitis and serological features identical to AIH type 1, is as prevalent as AIH, but it affects boys and girls equally. The differential diagnosis relies on cholangiographic studies. In autoimmune sclerosing cholangitis, liver parenchymal damage responds satisfactorily to immunosuppressive treatment, whereas bile duct disease tends to progress.

KEYWORDS

Autoimmune hepatitis - sclerosing cholangitis - children

REFERENCES

  • 1 Vergani D, Mieli-Vergani G. Autoimmune hepatitis. Textbook of Hepatology: From Basic Science to Clinical Practice. 3rd ed. Oxford, UK; Blackwell Publishing 2007: 1089-1101
    Google Scholar
  • 2 Gregorio G V, Portmann B, Reid F et al.. Autoimmune hepatitis in childhood: a 20-year experience.  Hepatology. 1997;  25(3) 541-547
    CrossrefPubMedGoogle Scholar
  • 3 Martini E, Abuaf N, Cavalli F, Durand V, Johanet C, Homberg J C. Antibody to liver cytosol (anti-LC1) in patients with autoimmune chronic active hepatitis type 2.  Hepatology. 1988;  8(6) 1662-1666
    PubMedGoogle Scholar
  • 4 Ma Y, Okamoto M, Thomas M G et al.. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease.  Hepatology. 2002;  35(3) 658-664
    CrossrefPubMedGoogle Scholar
  • 5 Donaldson P T. Genetics in autoimmune hepatitis.  Semin Liver Dis. 2002;  22(4) 353-364
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 6 Ma Y, Bogdanos D P, Hussain M J et al.. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2.  Gastroenterology. 2006;  130(3) 868-882
    CrossrefPubMedGoogle Scholar
  • 7 Fainboim L, Cañero Velasco M C, Marcos C Y et al.. Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA-DRB*1301, a marker for pediatric autoimmune hepatitis.  Hepatology. 2001;  33(6) 1512-1517
    CrossrefPubMedGoogle Scholar
  • 8 Pando M, Larriba J, Fernandez G C et al.. Pediatric and adult forms of type I autoimmune hepatitis in Argentina: evidence for differential genetic predisposition.  Hepatology. 1999;  30(6) 1374-1380
    CrossrefPubMedGoogle Scholar
  • 9 Vergani D, Wells L, Larcher V F et al.. Genetically determined low C4: a predisposing factor to autoimmune chronic active hepatitis.  Lancet. 1985;  2(8450) 294-298
    PubMedGoogle Scholar
  • 10 Liston A, Lesage S, Gray D H, Boyd R L, Goodnow C C. Genetic lesions in T-cell tolerance and thresholds for autoimmunity.  Immunol Rev. 2005;  204 87-101
    CrossrefPubMedGoogle Scholar
  • 11 Simmonds M J, Gough S C. Genetic insights into disease mechanisms of autoimmunity.  Br Med Bull. 2004;  71 93-113
    CrossrefPubMedGoogle Scholar
  • 12 Ahonen P, Myllärniemi S, Sipilä I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients.  N Engl J Med. 1990;  322(26) 1829-1836
    CrossrefPubMedGoogle Scholar
  • 13 Johnson P J, McFarlane I G. Meeting report: International Autoimmune Hepatitis Group.  Hepatology. 1993;  18(4) 998-1005
    CrossrefPubMedGoogle Scholar
  • 14 Alvarez F, Berg P A, Bianchi F B et al.. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis.  J Hepatol. 1999;  31(5) 929-938
    CrossrefPubMedGoogle Scholar
  • 15 Hennes E M, Zeniya M, Czaja A J International Autoimmune Hepatitis Group et al. Simplified criteria for the diagnosis of autoimmune hepatitis.  Hepatology. 2008;  48(1) 169-176
    CrossrefPubMedGoogle Scholar
  • 16 Vergani D, Alvarez F, Bianchi F B International Autoimmune Hepatitis Group et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group.  J Hepatol. 2004;  41(4) 677-683
    CrossrefPubMedGoogle Scholar
  • 17 Gregorio G V, Bracken P, Mieli-Vergani G, Vergani D. Prevalence of antibodies to hepatitis C and herpes simplex virus type 1 is not increased in children with liver kidney microsomal type 1 autoimmune hepatitis.  J Pediatr Gastroenterol Nutr. 1996;  23(5) 534-537
    CrossrefPubMedGoogle Scholar
  • 18 Gregorio G V, Pensati P, Iorio R, Vegnente A, Mieli-Vergani G, Vergani D. Autoantibody prevalence in children with liver disease due to chronic hepatitis C virus (HCV) infection.  Clin Exp Immunol. 1998;  112(3) 471-476
    CrossrefPubMedGoogle Scholar
  • 19 Dhawan A, Taylor R M, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation.  Liver Transpl. 2005;  11(4) 441-448
    CrossrefPubMedGoogle Scholar
  • 20 Cotler S J, Kanji K, Keshavarzian A, Jensen D M, Jakate S. Prevalence and significance of autoantibodies in patients with non-alcoholic steatohepatitis.  J Clin Gastroenterol. 2004;  38(9) 801-804
    CrossrefPubMedGoogle Scholar
  • 21 Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Büschenfelde K H. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen.  Lancet. 1987;  1(8528) 292-294
    PubMedGoogle Scholar
  • 22 Costa M, Rodríguez-Sánchez J L, Czaja A J, Gelpí C. Isolation and characterization of cDNA encoding the antigenic protein of the human tRNP(Ser)Sec complex recognized by autoantibodies from patients with type-1 autoimmune hepatitis.  Clin Exp Immunol. 2000;  121(2) 364-374
    CrossrefPubMedGoogle Scholar
  • 23 Wies I, Brunner S, Henninger J et al.. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis.  Lancet. 2000;  355(9214) 1510-1515
    CrossrefPubMedGoogle Scholar
  • 24 Gassert D J, Garcia H, Tanaka K, Reinus J F. Corticosteroid-responsive cryptogenic chronic hepatitis: evidence for seronegative autoimmune hepatitis.  Dig Dis Sci. 2007;  52(9) 2433-2437
    CrossrefPubMedGoogle Scholar
  • 25 Senaldi G, Portmann B, Mowat A P, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis.  Arch Dis Child. 1992;  67(12) 1447-1453
    PubMedGoogle Scholar
  • 26 Longhi M S, Mitry R R, Samyn M et al.. Vigorous activation of monocytes in juvenile autoimmune liver disease escapes the control of regulatory T-cells.  Hepatology. 2009;  , February 18 (Epub ahead of print)
    PubMedGoogle Scholar
  • 27 Longhi M S, Ma Y, Bogdanos D P, Cheeseman P, Mieli-Vergani G, Vergani D. Impairment of CD4(+)CD25(+) regulatory T-cells in autoimmune liver disease.  J Hepatol. 2004;  41(1) 31-37
    CrossrefPubMedGoogle Scholar
  • 28 Longhi M S, Ma Y, Mitry R R et al.. Effect of CD4+CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis.  J Autoimmun. 2005;  25(1) 63-71
    PubMedGoogle Scholar
  • 29 Longhi M S, Hussain M J, Mitry R R et al.. Functional study of CD4 + CD25 + regulatory T cells in health and autoimmune hepatitis.  J Immunol. 2006;  176(7) 4484-4491
    PubMedGoogle Scholar
  • 30 Longhi M S, Meda F, Wang P et al.. Expansion and de novo generation of potentially therapeutic regulatory T cells in patients with autoimmune hepatitis.  Hepatology. 2008;  47(2) 581-591
    CrossrefPubMedGoogle Scholar
  • 31 Longhi M S, Hussain M J, Bogdanos D P et al.. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2.  Hepatology. 2007;  46(2) 472-484
    CrossrefPubMedGoogle Scholar
  • 32 Alvarez F. Autoimmune hepatitis and primary sclerosing cholangitis.  Clin Liver Dis. 2006;  10(1) 89-107, vi
    CrossrefPubMedGoogle Scholar
  • 33 Saadah O I, Smith A L, Hardikar W. Long-term outcome of autoimmune hepatitis in children.  J Gastroenterol Hepatol. 2001;  16(11) 1297-1302
    CrossrefPubMedGoogle Scholar
  • 34 Ferreira A R, Roquete M L, Toppa N H, de Castro L P, Fagundes E D, Penna F J. Effect of treatment of hepatic histopathology in children and adolescents with autoimmune hepatitis.  J Pediatr Gastroenterol Nutr. 2008;  46(1) 65-70
    CrossrefPubMedGoogle Scholar
  • 35 Sogo T, Fujisawa T, Inui A et al.. Intravenous methylprednisolone pulse therapy for children with autoimmune hepatitis.  Hepatol Res. 2006;  34(3) 187-192
    PubMedGoogle Scholar
  • 36 Al-Chalabi T, Heneghan M A. Remission in autoimmune hepatitis: what is it, and can it ever be achieved?.  Am J Gastroenterol. 2007;  102(5) 1013-1015
    CrossrefPubMedGoogle Scholar
  • 37 Kerkar N, Annunziato R A, Foley L et al.. Prospective analysis of nonadherence in autoimmune hepatitis: a common problem.  J Pediatr Gastroenterol Nutr. 2006;  43(5) 629-634
    PubMedGoogle Scholar
  • 38 Czaja A J, Bianchi F B, Carpenter H A et al.. Treatment challenges and investigational opportunities in autoimmune hepatitis.  Hepatology. 2005;  41(1) 207-215
    CrossrefPubMedGoogle Scholar
  • 39 Mieli-Vergani G, Bargiota K, Samyn M, Vergani D. Therapeutic aspects of autoimmune liver disease in children. In: Dienes HP, Leuschner U, Lohse AW, Manns MP Autoimmune Liver Diseases—Falk Symposium. Vol. 142. Dordrecht; Springer 2005: 278-282
    Google Scholar
  • 40 Mieli-Vergani G, Vergani D. Autoimmune hepatitis in children.  Clin Liver Dis. 2002;  6(3) 623-634
    PubMedGoogle Scholar
  • 41 Czaja A J, Freese D K. American Association for the Study of Liver Disease . Diagnosis and treatment of autoimmune hepatitis.  Hepatology. 2002;  36(2) 479-497
    CrossrefPubMedGoogle Scholar
  • 42 Czaja A J, Menon K V, Carpenter H A. Sustained remission after corticosteroid therapy for type 1 autoimmune hepatitis: a retrospective analysis.  Hepatology. 2002;  35(4) 890-897
    CrossrefPubMedGoogle Scholar
  • 43 Krawitt E L. Autoimmune hepatitis.  N Engl J Med. 2006;  354(1) 54-66
    CrossrefPubMedGoogle Scholar
  • 44 Rumbo C, Emerick K M, Emre S, Shneider B L. Azathioprine metabolite measurements in the treatment of autoimmune hepatitis in pediatric patients: a preliminary report.  J Pediatr Gastroenterol Nutr. 2002;  35(3) 391-398
    CrossrefPubMedGoogle Scholar
  • 45 Alvarez F, Ciocca M, Cañero-Velasco C et al.. Short-term cyclosporine induces a remission of autoimmune hepatitis in children.  J Hepatol. 1999;  30(2) 222-227
    CrossrefPubMedGoogle Scholar
  • 46 Cuarterolo M, Ciocca M, Velasco C C et al.. Follow-up of children with autoimmune hepatitis treated with cyclosporine.  J Pediatr Gastroenterol Nutr. 2006;  43(5) 635-639
    CrossrefPubMedGoogle Scholar
  • 47 Johnson P J, McFarlane I G, Williams R. Azathioprine for long-term maintenance of remission in autoimmune hepatitis.  N Engl J Med. 1995;  333(15) 958-963
    CrossrefPubMedGoogle Scholar
  • 48 Aw M M, Dhawan A, Samyn M, Bargiota A, Mieli-Vergani G. Mycophenolate mofetil as rescue treatment for autoimmune liver disease in children: a 5-year follow-up.  J Hepatol. 2009;  , April 9 (Epub ahead of print)
    PubMedGoogle Scholar
  • 49 Gregorio G V, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease.  Autoimmunity. 2002;  35(8) 515-519
    CrossrefPubMedGoogle Scholar
  • 50 Duclos-Vallée J C, Sebagh M, Rifai K et al.. A 10 year follow up study of patients transplanted for autoimmune hepatitis: histological recurrence precedes clinical and biochemical recurrence.  Gut. 2003;  52(6) 893-897
    CrossrefPubMedGoogle Scholar
  • 51 Kerkar N, Hadzić N, Davies E T et al.. De-novo autoimmune hepatitis after liver transplantation.  Lancet. 1998;  351(9100) 409-413
    CrossrefPubMedGoogle Scholar
  • 52 Gregorio G V, Portmann B, Karani J et al.. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study.  Hepatology. 2001;  33(3) 544-553
    CrossrefPubMedGoogle Scholar
  • 53 Underhill J, Ma Y, Bogdanos D P, Cheeseman P, Mieli-Vergani G, Vergani D. Different immunogenetic background in autoimmune hepatitis type 1, type 2 and autoimmune sclerosing cholangitis.  J Hepatol. 2002;  36(Suppl 1) 156A
    PubMedGoogle Scholar
  • 54 Mitchell S A, Bansi D S, Hunt N, Von Bergmann K, Fleming K A, Chapman R W. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.  Gastroenterology. 2001;  121(4) 900-907
    CrossrefPubMedGoogle Scholar
  • 55 Scalori A, Heneghan M A, Hadzic N, Vergani D, Mieli-Vergani G. Outcome and survival in childhood onset autoimmune sclerosing cholangitis and autoimmune hepatitis: a 13-year follow up study.  Hepatology. 2007;  46(Suppl) 555A
    PubMedGoogle Scholar

 Professor
Giorgina Mieli-VerganiM.D. Ph.D. 

Paediatric Liver Centre, King's College Hospital, Denmark Hill

London SE5 9RS, United Kingdom

eMail: giorgina.vergani@kcl.ac.uk

      >